Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Kia Motesharei, PhD as its new senior vice president of Business Development & Corporate Strategy, it was reported on Tuesday.
In the new role, Dr Motesharei is to manage business development activities at Akcea and will continue to improve the corporate strategy in collaboration with the Akcea leadership team.
Dr Motesharei has over 20 years of business and corporate development and strategy experience with multinational companies. Prior to joining Akcea Therapeutics, Dr Motesharei served Merck KGaA for six-years, where he most recently served as vice president and global head of Licensing and Business Development, Neurology & Immunology. He has also held the positions of vice president of Business Development & Alliance Management at Dyax Corp, chief business Officer at Genfit and vice president of Corporate Development at ActivX.
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits